Skip to content

Type 1 Diabetes Reference

Type 1 diabetes is a chronic autoimmune disease in which the immune system destroys the pancreatic beta cells that produce insulin. The pancreas consequently makes little or no insulin, and the person requires continuing insulin replacement to move glucose from the bloodstream into cells. Diet and lifestyle do not cause type 1 diabetes, and lifestyle changes cannot replace insulin.

Overview

Insulin deficiency causes glucose to accumulate in the bloodstream while cells cannot use it normally for energy. Before diagnosis, this can produce increased thirst, frequent urination, hunger, fatigue, blurred vision, and unintentional weight loss. Symptoms can develop quickly or become recognizable over a longer period. Some people are first diagnosed during diabetic ketoacidosis, but ketoacidosis is not required for diagnosis.

Insulin treatment makes long-term survival possible, but treatment does not remove the condition. Food, physical activity, sleep, pain, infection, stress hormones, medication, alcohol, insulin absorption, and device function can all change glucose needs. Management therefore depends on repeated decisions rather than one fixed dose or routine.

Terminology and Classification

‘’Type 1 diabetes mellitus’’ and ‘’type 1 diabetes’’ are the standard clinical terms. ‘’Juvenile diabetes’’ became outdated because type 1 diabetes can begin at any age. ‘’Insulin-dependent diabetes mellitus’’ also fell out of routine use because insulin dependence does not by itself identify the disease mechanism.

Type 1 and type 2 diabetes both cause hyperglycemia but have different principal mechanisms. Type 1 diabetes is defined by severe insulin deficiency, usually caused by autoimmunity. Type 2 diabetes principally involves insulin resistance and progressive beta-cell dysfunction. A person with either type may use insulin, so treatment alone does not classify the condition.

Causes and Risk Factors

Most type 1 diabetes is immune-mediated. Genetic susceptibility contributes to risk, but inheritance is not simple or deterministic. Researchers have investigated viral and other environmental triggers, yet no single exposure explains every case. Type 1 diabetes cannot be prevented by eating less sugar, losing weight, exercising, or following a particular diet.

Type 1 diabetes is also associated at the population level with other autoimmune diseases, especially autoimmune thyroid disease and celiac disease. That association supports appropriate screening; it does not establish another autoimmune diagnosis in an individual person.

Symptoms and Presentation

Common presenting features include increased thirst, increased urination, fatigue, hunger, blurred vision, dehydration, and weight loss. Children may resume bed-wetting, struggle at school, become irritable, or lose physical stamina. Presentation varies, and a person may compensate for symptoms or have them attributed to stress, growth, infection, or another condition before glucose testing occurs.

Acute Glucose Changes

Hypoglycemia generally means glucose below 70 mg/dL, while readings below 54 mg/dL mark clinically significant hypoglycemia in standard reporting. Symptoms can include hunger, shaking, sweating, dizziness, irritability, visual or speech changes, confusion, and weakness. Severe hypoglycemia impairs the person’s ability to treat independently and can cause seizure or loss of consciousness. Fast-acting carbohydrate can treat many conscious-person lows; severe episodes may require glucagon and emergency help.

Hyperglycemia can cause thirst, urination, fatigue, blurred vision, headache, nausea, and difficulty concentrating. A high reading is interpreted with symptoms, recent food, insulin on board, illness, ketones, device function, and the person’s individualized care plan rather than one universal correction rule.

Diabetic ketoacidosis develops when severe insulin deficiency leads to ketone production, dehydration, and metabolic acidosis. Nausea, vomiting, abdominal pain, deep or rapid breathing, fruity-smelling breath, increasing fatigue, and altered consciousness can accompany it. DKA requires urgent hospital treatment with fluids, insulin, electrolyte management, monitoring, and treatment of the precipitating problem.

Diagnosis and Differential Diagnosis

Diagnosis uses plasma-glucose or A1C criteria together with the person’s symptoms and clinical state. Marked hyperglycemia with classic symptoms can establish diabetes promptly, while repeat testing may be needed when results and presentation do not align. Autoantibody testing and measures of endogenous insulin production can help distinguish type 1 diabetes from type 2 diabetes, monogenic diabetes, medication-related hyperglycemia, stress hyperglycemia, and other causes.

The onset of symptoms and the date of diagnosis are separate facts. A person may experience polyuria, thirst, weight loss, fatigue, or declining function before clinicians order or correctly interpret the testing that confirms diabetes.

Treatment and Management

People with type 1 diabetes require insulin every day. Insulin may be delivered through multiple daily injections or an insulin pump. Pump therapy uses rapid-acting insulin for continuing basal delivery and user-initiated meal or correction doses. Because interruption can remove basal insulin quickly, pump users need training, supplies, and a backup plan for failed infusion sites, damaged devices, depleted insulin, or loss of power.

Glucose can be checked through capillary blood-glucose monitoring and continuous glucose monitoring. A real-time CGM measures glucose in interstitial fluid, sends repeated readings and trend information to a compatible receiver or application, and can warn of predicted high or low glucose. CGM users still need access to a blood-glucose meter for device gaps and for situations in which symptoms do not match sensor readings.

Automated insulin delivery combines a CGM, insulin pump, and dosing algorithm. Depending on the system, the algorithm can increase, reduce, or pause insulin and can deliver automated correction doses. Hybrid systems still require user participation, including meal information and responses to alerts. Device choice depends on the person’s preferences, access, skills, support, body, and willingness to use the system.

Management also includes diabetes education, carbohydrate estimation or counting when used in the selected regimen, activity and illness planning, ketone guidance, hypoglycemia preparedness, psychosocial care, and screening for complications and associated conditions. Glucose and A1C goals are individualized. A number outside range is clinical information, not proof of effort, morality, or competence.

Course, Prognosis, and Complications

Type 1 diabetes is lifelong. Glucose needs and management capacity change with growth, puberty, pregnancy, aging, physical activity, acute illness, disability, pain, medication, work demands, cognition, and available care. Equipment can reduce risk and workload without eliminating either.

Acute complications include hypoglycemia and DKA. Long-term hyperglycemia can damage the retina, kidneys, peripheral and autonomic nerves, cardiovascular system, and feet. Blood-pressure and lipid management, eye and kidney screening, foot and neurological assessment, dental care, and individualized cardiovascular-risk management remain part of long-term care. The course and combination of complications vary from person to person.

Historical Context and Medical Evolution

Before insulin treatment began in 1922, type 1 diabetes was usually fatal. Animal-source insulin, human insulin, insulin analogs, home glucose meters, pumps, CGMs, and automated insulin delivery progressively changed survival and daily management. Access remained uneven, and each improvement introduced new training, supply, insurance, compatibility, and device-failure demands.

The United States authorized the Dexcom G6 in 2018. The interoperable Tandem t:slim X2 pump was authorized in 2019, and Tandem commercially launched Control-IQ integration with Dexcom G6 in January 2020. Dexcom G7 launched in the United States in February 2023, and Tandem launched t:slim X2 software that supported either Dexcom G6 or G7 in December 2023. Both the G6 configuration used by Logan in late 2024 and his later G7 upgrade were therefore available during their documented periods.

Associated Characters

Logan Weston

Main article: Logan Weston

Logan developed excessive thirst, frequent urination, and fatigue at age ten. Julia Weston recognized the pattern and repeatedly sought further testing, but the response was delayed for months. In 2019, when Logan was eleven, an emergency evaluation found glucose above 300 mg/dL, and subsequent testing established type 1 diabetes.

Logan began using a Dexcom G6 continuous glucose monitor during his early management. By late 2024 and early 2025, he paired the G6 with a Tandem t:slim X2 insulin pump running Control-IQ. The system displayed glucose data on his iPhone and Apple Watch, while the pump used the CGM data for automated basal adjustment and correction support. Logan still counted carbohydrates, entered meals, reviewed trends, and intervened manually because he preferred a system that preserved detailed control.

Later in 2025, by the time he began Howard University, Logan upgraded from the Dexcom G6 to the Dexcom G7 while retaining the Tandem t:slim X2 and Control-IQ system. The G7 continued to supply readings to his phone, watch, and pump. Julia and Nathan received shared readings through Dexcom Follow during adolescence; Charlie later became the principal person with shared access.

Logan usually wore the sensor on the back of his upper arm and rotated sites to protect his skin. The device made continuing data available without making every management task visible to other people. Its alerts could still be muted or ignored. During the CCBC presentation collapse in March 2025, Logan continued presenting after repeated warnings as his glucose fell from 63 to 54 mg/dL. He lost consciousness at the podium, and emergency personnel measured 48 mg/dL in the field.

At Howard, dining-hall estimates, disrupted sleep, changing activity, homesickness, and academic pressure made previously familiar calculations less predictable. Julia and Nathan chose a meal plan that guaranteed regular access to food after the CCBC collapse. Their standard emphasized consistent eating, use of the information available, correction when needed, and safety rather than perfect carbohydrate counts or punishment around food.

The December 12, 2025 collision damaged Logan’s pump and CGM. While he was unconscious and critically ill, hospital staff used institutional glucose monitoring and insulin management. Returning to his own pump and CGM during recovery restored a daily task and a degree of bodily control that the injury and hospitalization had removed.

After the collision, pain, medication, altered sensation, cognitive fatigue, mobility changes, illness, and later autonomic complications added variables to glucose management. Predictive alerts and shared data became more important, while Logan continued to manage diabetes alongside incomplete spinal cord injury, severe traumatic brain injury, chronic neuropathic pain, and asplenia.

Charlie kept Lolo’s Oh Shit Kit stocked with fast-acting carbohydrate, stabilizing food, glucagon, and spare infusion supplies. Logan also carried emergency glucose, backup supplies, and medical information in his daily bag. This preparation did not prevent every severe low. During the January 2035 Berlin crisis, rescue exertion, extreme stress, missed food, pain, and prolonged wakefulness preceded a 30–40 mg/dL hypoglycemic collapse that required hospital treatment.

Logan’s medical training improved his technical knowledge and access without making his body perfectly predictable. His experience of delayed diagnosis, daily insulin dependence, visible equipment, school and work pressures, and the need to be believed influenced his later clinical practice and advocacy.

Daily Life and Accessibility

Daily management can include glucose checks, trend interpretation, meal dosing, insulin-on-board calculations, infusion and sensor changes, charging, supply storage, site care, exercise planning, sick-day decisions, pharmacy and insurance work, and emergency preparation. The workload continues during school, travel, employment, illness, caregiving, and sleep.

Children and adolescents need developmentally appropriate family involvement without either premature transfer of all responsibility or unnecessary removal of autonomy. School planning can include trained personnel, immediate access to glucose and water, bathroom access, permission to check and treat in class, secure supplies, and participation in field trips, sports, and other activities.

Data sharing can support safety, especially during sleep, severe hypoglycemia, disability, or major life transitions. It can also create conflict over surveillance and independence. The person with diabetes, caregivers, and clinical team determine access according to age, safety, consent, and changing capacity.

Comorbidities and Condition Interactions

Illness, infection, surgery, pain, sleep disruption, reduced food intake, vomiting, corticosteroids, and other medications can alter glucose or insulin needs. A second disability can also change dexterity, cognition, sensation, communication, mobility, meal access, charging, site placement, or the ability to respond to an alert. Care planning addresses the specific interaction rather than assuming that one diagnosis produces a universal diabetes pattern.

During hospitalization, a person may continue personal CGM or automated insulin delivery when clinically appropriate, supported by supplies, trained staff, confirmatory point-of-care testing, institutional policy, and the person’s capacity to self-manage. Critical illness, impaired consciousness, surgery, damaged equipment, or unstable insulin needs can require hospital monitoring and another insulin plan.

Medical-System Interactions

Insulin, sensors, pump supplies, blood-glucose strips, glucagon, education, specialist care, and complication screening require continuing access. Insurance restrictions, prior authorization, formulary changes, supply interruptions, device compatibility, pharmacy delays, cost, housing, food access, and reliable electricity or internet can all affect safety.

Technology use and outcomes have not been distributed evenly across race and income. Clinical judgment can also be distorted when thirst, fatigue, weight change, school difficulty, or a caregiver’s observations are dismissed. Logan’s months-long diagnostic delay occurred despite Julia’s medical training and repeated advocacy, making listening and timely testing part of the condition’s documented medical-system history.

Public and Community Context

People with type 1 diabetes may use ‘’person with diabetes’‘, ‘’diabetic’‘, or another self-description according to individual preference. Language that treats glucose readings as good or bad behavior can turn clinical data into judgment. Food is part of insulin planning, but a single food did not cause the autoimmune disease, and insulin is not a punishment for eating.

Devices can be life-sustaining and still inconvenient, painful, visible, expensive, fallible, or intrusive. Competent self-management does not guarantee stable readings, and needing assistance during a low, illness, device failure, or hospitalization does not erase the person’s expertise.

Sources

Medical Conditions Endocrine Conditions Autoimmune Conditions Chronic Conditions Type 1 Diabetes Logan Weston